Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Balestro (Padova, Italy), E. Cocconcelli (Padova, Italy), D. Biondini (Padova, Italy), F. Fracasso (Padova, Italy), G. Castelli (Padova, Italy), G. Marulli (Padova, Italy), F. Rea (Padova, Italy), M. Cosio (Padova, Italy), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy). Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF). 2929

Member's Comments

No comment yet.

Related content which might interest you: Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Serum ST2 in Idiopathic Pulmonary Fibrosis (IPF): a possible new biomarker of disease? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD) Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Lymphocyte to monocyte ratio (LMR) predicts survival in patients with Idiopathic Pulmonary Fibrosis (IPF). Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017